![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Release First Quarter Financials on May 8 and to Present at 11th Annual JMP Research Conference on May 14
May 01, 2012 06:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., May 1, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will release its first quarter financials after the market close on May 8, 2012 and that it will...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces Intent to File NDA for Serada for Treatment of Menopausal Hot Flashes
April 17, 2012 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Type B pre-NDA meeting with the United States Food and Drug Administration...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces Receipt of $2.5 Million License Fee From Boehringer Ingelheim
March 28, 2012 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 28, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has received the remaining license fee payment resulting from its collaboration with...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Present at 24th Annual Roth Growth Stock Conference
March 12, 2012 14:15 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 12, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that James A. Schoeneck, Depomed's President and CEO, will be presenting at the 24th Annual Roth...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Reports Fourth Quarter and Year-End 2011 Financial Results
March 08, 2012 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the fourth quarter and year ended December 31, 2011.
2011 Business...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Files Patent Infringement Lawsuit Against Gralise(R) ANDA Filers
March 05, 2012 06:30 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 5, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced it has filed a patent infringement lawsuit in the United States District Court for the District of New...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Announce Fourth Quarter and Year-End Financial Results on March 8, 2012
March 01, 2012 06:30 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 1, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will release fourth quarter and year-end financial results after the market closes on Thursday...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Present at Citi 2012 Global Healthcare Conference and RBC Capital Markets Healthcare Conference
February 22, 2012 10:15 ET
|
Depomed, Inc.
MENLO PARK, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will be presenting at the Citi 2012 Global Healthcare Conference and the RBC Capital Markets...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces FDA Approval of Merck's JANUMET(R) XR That Accesses Depomed Patents Licensed to Merck
February 03, 2012 16:15 ET
|
Depomed, Inc.
MENLO PARK, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration (FDA) approved...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces Initiation of Phase 2 Clinical Study in Parkinson's Disease
January 24, 2012 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., Jan. 24, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has initiated a Phase 2 clinical trial of DM-1992, Depomed's novel gastric-retentive,...